Its a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1
Not, not an exacerbation of POTS, just that, you know, let's say her baseline, her rate is 60 and maybe it was 65
These steps help reduce side effects and improve comfort during GLP-1 therapy
Potential Side Effects Although both peptides are well-tolerated, some patients may experience: Mild water retention Joint stiffness (temporary) Insulin sensitivity changes (rare) Injection site irritation Patients should always be monitored by a physician trained in peptide therapy, and adjustments can be made to dose or frequency to mitigate any issues
Semaglutide, conversely, has stronger clinical backing
Key Characteristics of Iparmorelin Type: Ghrelin receptor agonist